Squarepoint’s Contineum Therapeutics CTNM Stock Holding History

Squarepoint’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192K	Sell	11,736 -48,108	-80%	-$631K	﹤0.01%	4078
2026 Q1	$782K	Buy	+59,844	New	+$803K	﹤0.01%	2981
2025 Q4	–	Sell	-13,086	Closed	-$154K	–	5018
2025 Q3	$154K	Sell	13,086 -76,328	-85%	-$615K	﹤0.01%	4021
2025 Q2	$355K	Sell	89,414 -41,613	-32%	-$181K	﹤0.01%	3557
2025 Q1	$915K	Sell	131,027 -86,212	-40%	-$784K	﹤0.01%	2751
2024 Q4	$3.18M	Sell	217,239 -132,761	-38%	-$2.1M	﹤0.01%	2011
2024 Q3	$6.7M	Buy	350,000 +200,000	+133%	+$3.83M	0.01%	1221
2024 Q2	$2.64M	Buy	+150,000	New	+$2.42M	﹤0.01%	1834

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Squarepoint's CTNM Position: Q2 2026 in Review

Squarepoint reduced its Contineum Therapeutics (CTNM) stake by 80% in Q2 2026, selling an estimated $631K and leaving 11,736 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #4078.

Squarepoint first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.7M in Q3 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Squarepoint held 11,736 shares of Contineum Therapeutics worth $192K as of Q2 2026.
Squarepoint sold 48,108 Contineum Therapeutics shares in Q2 2026, an estimated $631K.
Contineum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4078 holding.
Squarepoint first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
Squarepoint's Contineum Therapeutics position peaked at $6.7M in Q3 2024.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.